Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabotegravir + rilpivirine and buprenorphine
- Development stage
- Unknown
- Lead developer
- ViiV Healthcare
- Modality
- Small Molecules
- Administration
- Intramuscular, Subcutaneous
01
Overview
This is not a single combination drug but rather two separate medications. Cabenuva is a complete regimen for HIV-1 treatment consisting of cabotegravir (an HIV-1 integrase strand transfer inhibitor) and rilpivirine (an HIV-1 non-nucleoside reverse transcriptase inhibitor) in an extended-release injectable suspension. Sublocade is an extended-release buprenorphine injection for the treatment of moderate to severe opioid use disorder. These medications are administered separately and are not formulated together as a single product.
- Brand names
- Cabenuva + Sublocade
- Other names
- cabotegravir + rilpivirine + buprenorphineCAB/RPV + XR-Blong-acting injectable HIV and OUD treatment
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseMOR (Mu opioid receptor)Integrase allosteric pocket (HIV)
Beyond the preview
Go deeper on cabotegravir + rilpivirine and buprenorphine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabotegravir + rilpivirine and buprenorphine.